| Overview |
| bs-1355R-APC-Cy7 |
| TANK Polyclonal Antibody, APC-Cy7 Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat |
| Specifications |
| APC-Cy7 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human TANK |
| 151-260/425 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 10010 |
| Cytoplasm, Nucleus |
| I TRAF; ITRAF; TRAF family member associated NF KAPPA B activator; TRAF family member associated NFKB activator; TRAF interacting protein; TRAF interacting protein TANK isoform a; I-TRAF; Tank; TANK_HUMAN; TRAF family member-associated NF-kappa-B activator; TRAF-interacting protein; TRAF interacting protein TANK isoform b; TRAF2. |
| TANK was initially identified as a novel TRAF-interacting protein that regulated TRAF-mediated signal transduction. Specifically, ligand binding by surface receptors in the tumor necrosis factor (TNF) receptor and Toll/interleukin-1 (IL-1) receptor families lead to the formation of a TRAF/TANK complex that mediates the activation of the transcription factor NF-kappaB. TANK is found in the cytoplasm and can bind to TRAF1, TRAF2, or TRAF3, thereby inhibiting TRAF function by sequestering the TRAFs in a latent state in the cytoplasm. For example, this protein can block TRAF2 binding to LMP1, the Epstein Barr virus transforming protein, and inhibit LMP1-mediated NF kappa B activation. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz